Request for Proposals (RFP) - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response
Office of Assistant Secretary for Preparedness and Response · BARDA - ASPR / DAAPPO / BARDA DCMA
Respond by: Nov 20, 2026, 5:00 PM UTC−521 days left
From SAM.gov's public data file generated Oct 29, 2026, 3:30 AM UTC; newest notice posted Oct 29, 2026; loaded into FedSub Oct 29, 2026, 5:46 AM UTC
Notice facts
Source: SAM.gov Contract Opportunities public data file
- Solicitation number
- 75A50126R00001_RFP_NPIVS_27
- Notice type
- Solicitation
- Posted
- Aug 17, 2026 · Amended Oct 26, 2026
- Response date
- Respond by Nov 20, 2026, 5:00 PM UTC−5
- Set-aside
- No Set aside used
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Product or service code
- AN12
- Place of performance
- Washington, DC 20024
- Contracting office
- BARDA - ASPR / DAAPPO / BARDA DCMA (75A501)WASHINGTON, DC 20515
- Agency
- Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response
Past prime awardees
Source: Award history, not a list of bidders on this notice
Past prime awardees · award history, not a list of bidders on this notice
170 companies held prime contracts from this office under NAICS 541714; 26 of them reported first-tier subawards to companies with NAICS 541714 in FedSub's records.
- BATTELLE MEMORIAL INSTITUTE · Reported first-tier subawards to 71 companies with NAICS 541714 in FedSub's records (latest Sep 2026).
24 more past prime awardees on Professional
Description
Source: SAM.gov Contract Opportunities public data file
BARDA seeks Contractor(s) to support the continuation of the Vaccine Medical Counermeasures (MCM's) for Pandemic Influenza Preparedness and Response Program. Contractors will furnish all the necessary services, qualified personnel, materials, supplies, equipment and facilities (U.S. facilities preferred) not otherwise provided by the USG as needed to provide MCMs, such as vaccines, antigens, and adjuvants, for pandemic preparedness and response or as required in response to a public health emergency; produce antigen and vaccines against influenza virus or other viruses with pandemic potential as required by BARDA; produce antigens, adjuvants, and/or vaccines to support USG efforts to further improve influenza vaccines (for which feasibility data is available); and support rapid regulatory decisions and manufacturing readiness by generating and submitting to FDA all relevant data (e.g., analytical, nonclinical, clinical, and/or chemistry, manufacturing, and controls (CMC)), including data generated during interpandemic periods. Mandatory Qualification Requirements: To be eligible for award, the Offeror must produce vaccines against influenza and influenza strains with pandemic potential; must demonstrate a successful experience in the manufacturing of influenza vaccine by: 1. Holding a U.S. influenza vaccine license; or 2. Have developed an influenza vaccine as evidenced by: a. Submission of a Biologics License Application (BLA) for seasonal or pandemic influenza vaccine Please see full solicitation details and proposal submission instructions detailed in attachments 01-21 of this notice.
Versions on SAM.gov
Source: SAM.gov Contract Opportunities public data file
Posted Oct 26, 2026SolicitationCurrent version
Respond by Nov 20, 2026, 5:00 PM UTC−5
Changed from the version before: Description
This version on SAM.gov (opens SAM.gov in a new tab)Posted Sep 11, 2026Solicitation
Respond by Nov 20, 2026, 5:00 PM UTC−5
Changed from the version before: Response date
This version on SAM.gov (opens SAM.gov in a new tab)Posted Aug 17, 2026Solicitation
Respond by Oct 30, 2026, 5:00 PM UTC−4
Changed from the version before: Title
This version on SAM.gov (opens SAM.gov in a new tab)Posted Aug 17, 2026Solicitation
Respond by Oct 30, 2026, 5:00 PM UTC−4
This version on SAM.gov (opens SAM.gov in a new tab)